Single Strain

UABIa-12

JUMP TO:
01
Summary

One study assessed the effects of the probiotic Bifidobacterium animalis subsp. lactis UABla-12 on various IBS symptoms and quality of life over a 42-day period. The main areas of focus were bowel habits, abdominal pain, abdominal distention, global IBS symptoms, and overall quality of life (QoL).

 

Key Findings:

 

  • Bowel Habits: The UABia-12 group saw significant improvements in stool form. Initially, 39.1% of participants reported having abnormal stool forms (types 1, 2, 6, and 7 on the Bristol Stool Scale). By day 42, 75.5% of these participants had transitioned to normal stool forms, with only 20% still experiencing abnormal forms. This change represented a 23.9% relative increase in normal stool forms and a 48.8% reduction in abnormal forms, a statistically significant difference (p=0.022; Cohen’s d = 0.43).

 

  • Abdominal Pain: For pain severity, 28.2% of participants in the UABia-12 group were classified as responders, with a >30% reduction in pain by day 42 (p=0.031; effect size = 0.43). Additionally, there was a 37.3% reduction in pain severity (p<0.001) and a 36.4% reduction in pain duration (p<0.001).

 

  • Abdominal Distention: The reduction in abdominal distention was significant compared to placebo (p<0.034), with an effect size of 0.26.

 

  • Global IBS Symptoms: The UABia-12 group had baseline mean IBS-SSS scores of 305.45, which improved by a 104.5-point reduction. This change exceeds the Minimum Clinically Important Difference (MCID) of 50 points for the IBS-SSS tool, indicating a meaningful improvement in symptoms. The improvement was statistically significant compared to placebo by day 42 (p<0.001), with an effect size of 0.53, indicating a moderate effect.

 

  • Quality of Life (QoL): Despite intragroup improvements in IBS-QoL, no significant differences were observed when compared to placebo. A significant effect on the Perceived Stress Scale (PSS) was noted at day 21 (p=0.030), though this effect was not sustained by the end of the study.

 

Key Takeaways:

The probiotic B. lactis UABia-12 shows promise as a therapeutic option for managing IBS symptoms. Beneficial effect sizes were observed for bowel habits, abdominal pain, abdominal distention, and IBS Symptom Severity scores, suggesting a small to moderate clinical benefit. These findings indicate that B. lactis UABia-12 may be helpful for IBS symptom management. Further research is recommended to confirm these results.

 

 

Dosing Instructions: 

Potentially Effective Dose(s) 10 billion CFU per day
Form Capsules; taken as one capsule per day before a meal with water 
Suggested Minimum 

Trial Duration

 6 weeks 

 

 

References:

Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UAB1a-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial.  Nutrients 2020;12:363. [doi: 10.3390/nu12020363

Read More…

One study assessed the effects of the probiotic Bifidobacterium animalis subsp. lactis UABla-12 on various IBS symptoms and quality of life over a 42-day period. The main areas of focus were bowel habits, abdominal pain, abdominal distention, global IBS symptoms, and overall quality of life (QoL).

 

Key Findings:

 

  • Bowel Habits: The UABia-12 group saw significant improvements in stool form. Initially, 39.1% of participants reported having abnormal stool forms (types 1, 2, 6, and 7 on the Bristol Stool Scale). By day 42, 75.5% of these participants had transitioned to normal stool forms, with only 20% still experiencing abnormal forms. This change represented a 23.9% relative increase in normal stool forms and a 48.8% reduction in abnormal forms, a statistically significant difference (p=0.022; Cohen’s d = 0.43).

 

  • Abdominal Pain: For pain severity, 28.2% of participants in the UABia-12 group were classified as responders, with a >30% reduction in pain by day 42 (p=0.031; effect size = 0.43). Additionally, there was a 37.3% reduction in pain severity (p<0.001) and a 36.4% reduction in pain duration (p<0.001).

 

  • Abdominal Distention: The reduction in abdominal distention was significant compared to placebo (p<0.034), with an effect size of 0.26.

 

  • Global IBS Symptoms: The UABia-12 group had baseline mean IBS-SSS scores of 305.45, which improved by a 104.5-point reduction. This change exceeds the Minimum Clinically Important Difference (MCID) of 50 points for the IBS-SSS tool, indicating a meaningful improvement in symptoms. The improvement was statistically significant compared to placebo by day 42 (p<0.001), with an effect size of 0.53, indicating a moderate effect.

 

  • Quality of Life (QoL): Despite intragroup improvements in IBS-QoL, no significant differences were observed when compared to placebo. A significant effect on the Perceived Stress Scale (PSS) was noted at day 21 (p=0.030), though this effect was not sustained by the end of the study.

 

Key Takeaways:

The probiotic B. lactis UABia-12 shows promise as a therapeutic option for managing IBS symptoms. Beneficial effect sizes were observed for bowel habits, abdominal pain, abdominal distention, and IBS Symptom Severity scores, suggesting a small to moderate clinical benefit. These findings indicate that B. lactis UABia-12 may be helpful for IBS symptom management. Further research is recommended to confirm these results.

 

 

Dosing Instructions: 

Potentially Effective Dose(s) 10 billion CFU per day
Form Capsules; taken as one capsule per day before a meal with water 
Suggested Minimum 

Trial Duration

 6 weeks 

 

 

References:

Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UAB1a-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial.  Nutrients 2020;12:363. [doi: 10.3390/nu12020363

Read More…
Find a probiotic with UABla-12

Evaluate products based on whether they transparently disclose all ingredients and their amounts, exclusively use probiotics tested in randomized placebo-controlled trials in IBS populations, and contain studied doses.

View products containing this strain >

One study assessed the effects of the probiotic Bifidobacterium animalis subsp. lactis UABla-12 on various IBS symptoms and quality of life over a 42-day period. The main areas of focus were bowel habits, abdominal pain, abdominal distention, global IBS symptoms, and overall quality of life (QoL).

 

Key Findings:

 

  • Bowel Habits: The UABia-12 group saw significant improvements in stool form. Initially, 39.1% of participants reported having abnormal stool forms (types 1, 2, 6, and 7 on the Bristol Stool Scale). By day 42, 75.5% of these participants had transitioned to normal stool forms, with only 20% still experiencing abnormal forms. This change represented a 23.9% relative increase in normal stool forms and a 48.8% reduction in abnormal forms, a statistically significant difference (p=0.022; Cohen’s d = 0.43).

 

  • Abdominal Pain: For pain severity, 28.2% of participants in the UABia-12 group were classified as responders, with a >30% reduction in pain by day 42 (p=0.031; effect size = 0.43). Additionally, there was a 37.3% reduction in pain severity (p<0.001) and a 36.4% reduction in pain duration (p<0.001).

 

  • Abdominal Distention: The reduction in abdominal distention was significant compared to placebo (p<0.034), with an effect size of 0.26.

 

  • Global IBS Symptoms: The UABia-12 group had baseline mean IBS-SSS scores of 305.45, which improved by a 104.5-point reduction. This change exceeds the Minimum Clinically Important Difference (MCID) of 50 points for the IBS-SSS tool, indicating a meaningful improvement in symptoms. The improvement was statistically significant compared to placebo by day 42 (p<0.001), with an effect size of 0.53, indicating a moderate effect.

 

  • Quality of Life (QoL): Despite intragroup improvements in IBS-QoL, no significant differences were observed when compared to placebo. A significant effect on the Perceived Stress Scale (PSS) was noted at day 21 (p=0.030), though this effect was not sustained by the end of the study.

 

Key Takeaways:

The probiotic B. lactis UABia-12 shows promise as a therapeutic option for managing IBS symptoms. Beneficial effect sizes were observed for bowel habits, abdominal pain, abdominal distention, and IBS Symptom Severity scores, suggesting a small to moderate clinical benefit. These findings indicate that B. lactis UABia-12 may be helpful for IBS symptom management. Further research is recommended to confirm these results.

 

 

Dosing Instructions: 

Potentially Effective Dose(s) 10 billion CFU per day
Form Capsules; taken as one capsule per day before a meal with water 
Suggested Minimum 

Trial Duration

 6 weeks 

 

 

References:

Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UAB1a-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial.  Nutrients 2020;12:363. [doi: 10.3390/nu12020363

02
Results
Overall evidence quality grade
90%

This probiotic has higher quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
Download
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UAB1a-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial

    • 2020
    • Martoni CJ, Srivastava S, Leyer GJ.

    • Nutrients 2020;12:363

    • DOI: 10.3390/nu12020363
    • 10 billion CFU
    • 6 weeks
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • MULTICENTER
      • PROSPECTIVE
      • THREE PARALLEL ARMS

    • ADULTS

    • ITT,PP (total) n=336,318
      ITT,PP (UABIa-12 ) n=111,105
      ITT,PP (DDS-1® ) n=113,107
      ITT,PP (placebo) n=109,106
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • No subtype specific statistical analysis was conducted. At baseline, n=21 (19.1%) of participants in the UABIa-12 group were classified as having diarrhea (a type 6 or 7 stool form on the Bristol stool scale).

      • By the end of treatment, n=12 (10.9%) of participants were classified as having constipation. This was a 42.9%% relative mean reduction in participants experiencing diarrhea from baseline till the end of treatment. This was a 55.1% relative therapeutic gain over the placebo group.

    • Constipation

      • No subtype specific statistical analysis was conducted. At baseline, n=22 (20%) of participants in the UABIa-12 group were classified as having constipation (a type 1 or 2 stool form on the bristol stool scale).

      • By the end of treatment, n=10 (9.1%) of participants were classified as having constipation. This was a 54.5% relative reduction in participants experiencing constipation from baseline till the end of treatment.

      • This was a 66.7% relative mean therapeutic gain over the placebo group, which experienced a higher occurrence of constipation by the end of treatment relative to baseline measurements.

    • Bowel Habits

      • Bowel habits were assessed using the IBS-SSS. The UABia-12 group experienced a mean absolute symptom score reduction of 17.86 points (a 28.3% relative reduction from baseline), which was statistically significant compared to placebo (p=0.001) by day 42 of the intervention.

      • The mean relative therapeutic gain over placebo was 15.1%. At baseline, 39.1% (43 out of 110) of participants in the UABia-12 group experienced abnormal stool forms (types 1, 2, 6, and 7 on the Bristol Stool Scale).

      • By day 42, 75.5% (83 out of 105) of participants in the UABia-12 group had normal stool forms, while only 20% (22 out of 105) continued to have abnormal stool forms. This represented a 23.9% relative increase in participants with normal stool forms and a 48.8% reduction in those with abnormal stool forms from baseline.

      • The relative therapeutic gain over placebo for reducing abnormal stool forms was 49%. Changes in bowel habits between the UABia-12 and placebo groups were statistically significant (p=0.022) by day 42.

      • We calculated an effect size of 0.43 for this parameter, which falls within our lowest effect size range. There were no statistically significant changes in stool frequency in the UABia-12 group.

    • Global IBS Symptoms

      • The UABIa-12 group had baseline mean IBS-SSS scores of 305.45, which improved by a 104.5 point reduction, exceeding the MCID for this validated measurement tool. This effect was statistically significant compared to placebo by day 42 (p<0.001).

      • The mean relative decrease in IBS-SSS total score was 34.2%. Relative mean therapeutic gain over placebo was 5.4%.

      • We calculated an effect size of 0.53 for this parameter, placing it within our moderate effect size range.

    • Abdominal Pain / Discomfort

      • Based on abdominal pain severity scores from the APS-NRS, the B.lactis UABIa-12 group had 28.2% of participants classified as abdominal pain responders by day 42, meaning they had a >30% reduction in abdominal pain severity (p=0.031). The therapeutic gain over placebo was 12.6%.

      • We calculated an effect size of 0.43 for this parameter which falls within our lowest effect size range.

      • Results from another screening tool used in the study called the IBS symptom severity score (IBS-SSS) also revealed significant benefits for abdominal pain severity and duration compared to the placebo group for the UABla-12 probiotic group.

      • For the abdominal pain severity parameter, there was a mean absolute reduction of 24.35 points (-37.3%) from baseline by day 42. This was statistically significant compared to placebo (p<0.001) and the UABIa-12 group had a mean therapeutic gain over placebo of 17.3%.

      • For abdominal pain duration, the UABla-12 group had an absolute mean reduction of 20.95 points (36.4%) by day 42 that was statistically significant compared to placebo (p<0.001). The mean therapeutic gain over placebo in the UABIa-12 group was 21.1%.

    • Bloating / Distention

      • Abdominal distention was assessed using the IBS-SSS. The UABIa-12 group experienced a mean absolute symptom score reduction of 21.90 points (37.0%), which was statistically significant compared to placebo (p<0.034). The mean relative therapeutic gain over placebo was 10.5%.

      • We calculated an effect size of 0.26 for this parameter, placing it within our lowest effect size range.

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • In participants taking B. lactis UABla-12, despite intragroup improvement in IBS-QoL, no significant differences were observed when compared to placebo.

      • Additionally, a significant effect was observed between B. lactis UABla-12 and placebo on the perceived stress scale (PSS) at day 21 (p = 0.030), however, no difference was observed at the end of study visit.

      • For the QOL measure on the IBS-SSS tool, the UABIa-12 group experienced a statistically significant mean relative improvement of 31.7% from baseline till day 42 (p=0.001). Therapeutic gain over placebo was 13.8%.

    • Miscellaneous Symptoms

      • No data

    • Notes

      • No data